Robot-Assisted Partial Nephrectomy for T1b Tumors: Strict Trifecta Outcomes
Overview
Authors
Affiliations
Background And Objectives: "Trifecta" in partial nephrectomy consists of negative surgical margins, minimal renal function decrease and absence of complications. In the present article, our single-center robot-assisted partial nephrectomy (RAPN) experience in T1b renal masses is reported in terms of strict Trifecta outcomes.
Methods: This is a retrospective analysis of patients with a tumor diameter between 4 and 7 cm (stage T1b), who underwent RAPN by a single surgeon. Preoperative, intraoperative, and postoperative data were recorded and analyzed to evaluate short-term functional and oncologic outcomes. Patients with absence of grade ≥ 2 Clavien-Dindo complications, warm ischemia time (WIT) ≤25 minutes, ≤15% postoperative estimated glomerular filtration rate (eGFR) decrease and negative surgical margins were reported to achieve strict Trifecta outcomes. < .05 was indicated statistically significant.
Results: A total of 150 patients underwent RAPN, and 50 patients were identified with tumor size between 4 and 7 cm. Mean WIT was 20.8 ± 6.2 minutes and mean estimated blood loss (EBL) was 269 ± 191 mL. Surgical margins were negative in all patients. Eleven patients (22%) had a >15% eGFR decrease after surgery. Nine patients (18%) had WIT longer than 25 minutes. Four patients (8%) had grade ≥2 Clavien-Dindo complications. Twenty-nine (58%) patients had strict Trifecta outcomes. Mean follow-up was 44.2 ± 27.2 months. Tumor recurrence was not observed in any patient.
Conclusions: Robot-assisted laparoscopic partial nephrectomy for T1b renal masses can be safely performed in experienced hands. Optimal strict Trifecta outcomes and recurrence rates can be achieved.
Umemoto T, Hasegawa M, Yuzuriha S, Kano T, Ogawa T, Kawakami M BMC Urol. 2023; 23(1):85.
PMID: 37158841 PMC: 10165753. DOI: 10.1186/s12894-023-01247-0.
Numakura K, Kobayashi M, Koizumi A, Kashima S, Yamamoto R, Nara T World J Surg Oncol. 2022; 20(1):202.
PMID: 35701769 PMC: 9199197. DOI: 10.1186/s12957-022-02669-0.
Iwamoto H, Nosaka K, Miyoshi H, Makishima K, Ochiai R, Shimizu R Yonago Acta Med. 2021; 64(4):345-352.
PMID: 34849083 PMC: 8612879. DOI: 10.33160/yam.2021.11.004.
Karamik K, Aktas Y, Erdemir A, Islamoglu E, Olcucu M, Ozsoy C J Kidney Cancer VHL. 2021; 8(4):1-12.
PMID: 34703725 PMC: 8490181. DOI: 10.15586/jkcvhl.v8i4.183.
Zeng S, Zhou Y, Wang M, Bao H, Na Y, Pan T Transl Androl Urol. 2021; 10(8):3386-3394.
PMID: 34532263 PMC: 8421827. DOI: 10.21037/tau-21-473.